ChinaBio Today
Contributor since: 2007
Company: ChinaBio LLC
Articles
Week In Review: Innovent Lands $305 Million Investment From Sanofi; Will Partner Two Candidates In China
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments
Week In Review: Henlius Signs $196 Million Deal For 2 Oncology Bifunctional Sialidase Candidates
Week In Review: invoX, A Sino Biopharm Company, To Pay $161 Million To Acquire F-Star
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Week In Review: Fosun Pays $158 Million For Controlling Stake In Singapore Medical Centers
Week In Review: Vivo Raises $600 Million In First Tranche Of China PE Fund
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Week In Review: Hengrui Launches U.S. Subsidiary To Bring Novel Medicines To Global Markets
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou
Week In Review: Harbour BioMed Signs $350 Million Out-License Deal For Bispecific With AstraZeneca
Week In Review: RemeGen Raises $410 Million In Shanghai IPO For mAb/Dual Therapies
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
Week In Review: A Possible Solution To U.S. De-Listing Of China Biopharmas?
Week In Review: Adiso Breaks Out Of Stealth With $95 Million From Morningside
Week In Review: Adagene Forms $2.5-Billion, Four-Drug Partnership With Sanofi
Week In Review: Huadong Pharma Enters $662 Million Deal For 2 Kiniksa Anti-Inflammatory Drugs
Week In Review: China's NMPA Approves Pfizer's Oral COVID-19 Therapy Paxlovid
Week In Review: U.S. FDA Rejects Innovent/Lilly PD-1 NDA Based On China-Only Trial Subjects
Week In Review: Biopharma Deals Slow During China New Year Week
Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal
Week In Review: Mabwell Bio Raises $547 Million In Shanghai STAR IPO
Week In Review: ChinaBio At China Showcase - The Golden Age For China Life Science Investing
Week In Review: China Biopharma Books $500 Million Of Deals To Start 2022
Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
Week In Review: BeiGene Raises $3.5 Billion In Shanghai STAR Board IPO
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xencor In $480 Million Deal
Week In Review: BeiGene Cleared To Stage $3 Billion IPO On Shanghai STAR Exchange
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
Week In Review: 2 China-Affiliated Biopharmas Raise $585 Million In IPOs
Week In Review: Fosun Pharma Acquires Majority Stake In China Vaccine Company For $682 Million
Week In Review: China's Hansoh Signs 2 siRNA Deals Worth $1.7 Billion